Last reviewed · How we verify
GnRH antagonist-Cetrorelix
Cetrorelix blocks gonadotropin-releasing hormone (GnRH) receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion.
Cetrorelix blocks gonadotropin-releasing hormone (GnRH) receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART), Prostate cancer (advanced), Endometriosis.
At a glance
| Generic name | GnRH antagonist-Cetrorelix |
|---|---|
| Also known as | Cetrotide |
| Sponsor | University of Edinburgh |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Cetrorelix is a GnRH antagonist that competitively binds to GnRH receptors on pituitary gonadotroph cells, rapidly suppressing the release of LH and FSH without an initial flare effect. This leads to immediate inhibition of sex hormone production (testosterone and estrogen), making it useful in reproductive medicine and hormone-sensitive conditions.
Approved indications
- Controlled ovarian hyperstimulation in assisted reproductive technology (ART)
- Prostate cancer (advanced)
- Endometriosis
Common side effects
- Injection site reactions
- Headache
- Hot flushes
- Ovarian hyperstimulation syndrome (OHSS)
- Nausea
Key clinical trials
- PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) (NA)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (PHASE3)
- NATural Ovarian Stimulation (PHASE4)
- Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF (NA)
- Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (NA)
- Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A (PHASE3)
- PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRH antagonist-Cetrorelix CI brief — competitive landscape report
- GnRH antagonist-Cetrorelix updates RSS · CI watch RSS
- University of Edinburgh portfolio CI